Predictive
Oncology (NASDAQ: POAI), a developer of highly adaptable assessment methods
for cancer patients to help guide personalized treatments, employs its
proprietary smart tumor profiling and artificial intelligence (“AI”) platform
to predict tumor drug response and improve clinical outcomes for cancer
patients. An article discussing the company’s activities further reads, “Last
year, POAI, then known as Precision Therapeutics, formed TumorGenesis to focus
on innovative ways to create improved patient-derived (PDx) tumor models.
Currently, TumorGenesis is working on developing new techniques for growing
tumors in the lab to generate more relevant models of the tumors that can be
used to test drugs for personalized therapy or aid in development of new
medications. . . .The approach is designed to grow tumors in the lab by
providing an environment that closely mimics the human body through the use of
chemistry, biology, mechanics and cell nutrients. In addition to this exclusive
technology being quicker and more affordable than existing PDx animal models,
researchers anticipate that the approach will better replicate the
characteristics of tumors. Initially, the company plans to develop PDx models
for multiple myeloma, triple-negative breast cancer and ovarian cancer, but
Predictive is expecting the technology to ultimately benefit oncologists who
are investigating other cancer areas as well, including liver, pancreatic, lung
and colon.”
To view the full article, visit http://ibn.fm/1cR8D
About Predictive Oncology Inc.
Predictive Oncology operates in two business areas: first,
applying artificial intelligence to personalized medicine and drug discovery to
provide personalized medicine solutions for patients and clinicians as well as
clients in the pharmaceutical, diagnostic and biotech industries; and second,
production of the FDA-approved STREAMWAY(R) System for automated, direct-to-drain
medical fluid disposal. For more information, visit the company’s website
at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
